Excess of mortality and mortality from COVID-19 and other causes of death in 2020 in Navarra, Spain
DOI:
https://doi.org/10.23938/ASSN.1018Keywords:
Mortality, Excess of mortality, COVID-19, Life expectancyAbstract
Background. In this study, we aimed to present mortality indicators from a database of death causes by age and sex in Navarre (Spain) for 2020: life expectancy at birth, excess mortality, and mortality from COVID-19 and other causes.
Methods. A Poisson regression model, which accounts for temporal trends in the previous years, was used to estimate the expected deaths by sex and age for 2020.
Results. Life expectancy at birth in Navarre for 2020 was 80.6 and 85.9 years for men and women, respectively, 1.4 and 1.0 years lower than in 2019. Deaths in people aged <55 years were similar to those expected. The highest adjusted excess mortality rate occurred among men and women aged ≥85 years, were 61% of excess deaths was concentrated. The estimated number of excess deaths did not exceed the number of reported deaths from COVID-19. In individuals aged >75 years, around 9 out of 10 people died from COVID-19. Coinciding with the COVID-19 pandemic, there was a remarkable decrease in mortality in people affected by diseases where dementia is included.
Conclusion. The first and second waves of the COVID-19 pandemic reduced life expectancy at birth to figures observed ten years ago. The increase in deaths in Navarre for 2020 is largely attributable to COVID-19.
Downloads
References
ZHU N, ZHANG D, WANG W, LI X, YANG B, SONG J et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727-733. https://doi.org/10.1056/NEJMoa2001017
CASTILLA J, MORENO-IRIBAS C, IBERO ESPARZA C, MARTÍNEZ-BAZ I, TROBAJO-SANMARTÍN C, EZPELETA C et al. Primera onda pandémica de COVID-19 en Navarra, febrero-junio 2020. An Sist Sanit Navar 2021; 45(1):e0954. https://doi.org/10.23938/ASSN.0954
MORGAN D, INO J, DI PAOLANTONIO G, MURTIN F. Excess mortality: Measuring the direct and indirect impact of COVID-19. OECD Health Working Papers 122, 2020. https://doi.org/10.1787/c5dc0c50-en
Ministerio de Ciencia e Innovación. Instituto de Salud Carlos III. Vigilancia de la Mortalidad Diaria (MoMo). Situación a 11 de enero de 2022. Gobierno de España. [Consultado el 12/01/2022]. https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Paginas/Informes_MoMo_2022.aspx
KONTIS V, BENNETT JE, RASHID T, et al. Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries. Nat Med 2020; 26: 1919-1928. https://doi.org/10.1038/s41591-020-1112-0
Organización Mundial de la Salud. Orientación internacional para la certificación y clasificación (codificación) del COVID-19 como causa de muerte. Basada en la CIE-Clasificación Estadística Internacional de Enfermedades y Problemas Relacionados con la Salud (20 de abril de 2020). https://www.paho.org/es/file/66130/download?token=0B9w7pTx
CIRERA L, SEGURA A, HERNÁNDEZ I. Defunciones por COVID-19: no están todas las que son y no son todas las que están. Gac Sanit; 35(6): 590-593. https://doi.org/10.1016/j.gaceta.2020.06.006
Centers for Disease Control and Prevention. CDC Newsroom. Overdose deaths accelerating during COVID-19. [Consultado el 10/02/2022]. https://www.cdc.gov/media/releases/2020/p1218-overdose-deaths-covid-19.html
LIU J, ZHANG L, YAN Y, ZHOU Y, YIN P, QI J et al. Excess mortality in Wuhan city and other parts of China during the three months of the covid-19 outbreak: findings from nationwide mortality registries. BMJ 2021; 372: n415. https://doi.org/10.1136/bmj.n415
CHIANG CL. The life table and its construction. In: Introduction to stochastic processes in biostatistics. New York: John Wiley & Sons, 1968; 189-214.
ISLAM N, SHKOLNIKOV VM, ACOSTA RJ, KLIMKIN I, KAWACHI I, IRIZARRY RA et al. Excess deaths associated with covid-19 pandemic in 2020: age and sex disaggregated time series analysis in 29 high income countries. BMJ 2021; 373: n1137. https://doi.org/10.1136/bmj.n1137
TOBÍAS A, SÁEZ M, GALÁN I. Herramientas gráficas para el análisis descriptivo de series temporales en la investigación médica. Med Clin (Barc) 2004; 122 (18): 701-706. https://doi.org/10.1016/S0025-7753(04)74361-4
SAEZ M, PÉREZ-HOYOS S, TOBIAS A, SAURINA C, BARCELÓ MA, BALLESTER F. Métodos de series temporales en los estudios epidemiológicos sobre contaminación atmosférica. Rev Esp Salud Publica 1999; 73(2): 133-143. https://scielo.isciii.es/pdf/resp/v73n2/metodos.pdf
DIEBOLB FX, MARIANO RS. Comparing predictive accuracy. J Bus Econ Stat 1995; 13: 253-265. https://doi.org/10.1198/073500102753410444
European Commission. Eurostat - Products manuals and guidelines. Revision of the European standard population - Report of Eurostat's task force - 2013 edition. https://ec.europa.eu/eurostat/documents/3859598/5926869/KS-RA-13-028-EN.PDF.pdf/e713fa79-1add-44e8-b23d-5e8fa09b3f8f?t=1414782757000
BOYLE P, PARKIN DM. Cancer registration: principles and methods. Statistical methods for registries. IARC Sci Publ 1991; (95): 126-158.
Instituto Nacional de Estadística. Esperanza de Vida al Nacimiento por comunidad autónoma, según sexo. [Consultado el 10/02/2022]. http://www.ine.es/jaxiT3/Tabla.htm?t=1448&L=0
POLLÁN M, PÉREZ-GÓMEZ B, PASTOR-BARRIUSO R, OTEO J, HERNÁN MA, PÉREZ-OLMEDA M et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 2020; 396(10250): 535-544. https://doi.org/10.1016/S0140-6736(20)31483-5
European Commission. Eurostat - Products Eurostat News. Life expectancy decreased in 2020 across the EU. [Consultado el 01/10/2021]. https://ec.europa.eu/eurostat/web/products-eurostat-news/-/edn-20210407-1
OECD. Health at a Glance 2021: OECD Indicators. https://doi.org/10.1787/ae3016b9-en
CASADO MI, LASANTA MJ, ÁLVAREZ-ARRUTI N, SOBEJANO I, MUGARRA I, GORRICHO J, SAENZ DE PIPAÓN I. Prevalencia de enfermedades crónicas según nivel socioeconómico en Navarra. XXXIV Jornadas de Economía de la Salud. Pamplona, 27-30 de mayo de 2014. https://www.aes.es/Jornadas2014/pdf/posters/Aes_2014_94_1.pdf
LEÓN-GÓMEZ I, MAZAGATOS C, DELGADO-SANZ C, FRÍAS L, VEGA-PIRIS L, ROJAS-BENEDICTO A et al. The Impact of COVID-19 on mortality in Spain: monitoring excess mortality (MoMo) and the surveillance of confirmed COVID-19 deaths. Viruses 2021; 13(12): 2423. https://doi.org/10.3390/v13122423
FLAXMAN S, MISHRA S, GANDY A, UNWIN HJT, MELLAN TA, COUPLAND H et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 2020; 584(7820): 257-261. https://doi.org/10.1038/s41586-020-2405-7
CASTILLA J, GUEVARA M, MIQUELEIZ A, BAIGORRIA F, IBERO-ESPARZA C, NAVASCUÉS A, the working group for the study of COVID-in Navarra. Risk factors of infection, hospitalization and death from SARS-CoV-2: a population-based cohort study. J Clin Med 2021; 10(12): 2608. https://doi.org/10.3390/jcm10122608
GRANDE E, FEDELI U, PAPPAGALLO M, CRIALESI R, MARCHETTI S, MINELLI G et al. Variation in cause-specific mortality rates in Italy during the first wave of the COVID-19 pandemic: a study based on nationwide data. Int J Environ Res Public Health 2022; 19(2): 805. https://doi.org/10.3390/ijerph19020805
AHMAD FB, ANDERSON RN. The leading causes of death in the US for 2020. JAMA 2021; 325(18): 1829-1830. https://doi.org/10.1001/jama.2021.5469
DARBÀ J, MARSÀ A. Results after 10 years of colorectal cancer screenings in Spain: hospital incidence and in-hospital mortality (2011-2016). PLoS One 2020; 15(2): e0228795. https://doi.org/10.1371/journal.pone.0228795
IDIGORAS I, ARROSPIDE A, PORTILLO I, ARANA-ARRI E, MARTÍNEZ-INDART L, MAR J et al. Evaluation of the colorectal cancer screening programme in the Basque Country (Spain) and its effectiveness based on the Miscan-colon model. BMC Public Health 2017; 18(1): 78. https://doi.org/10.1186/s12889-017-4639-3
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
